Skip to Main Content

It’s been a frenetic and fraught week in pharma and biotech, as deals were forged and unveiled at J.P. Morgan — and the markets reacted to our president-elect’s sharp denunciation of the drug industry. So there were some clear winners and losers:


Peter Thiel seems to be expanding his influence in health care: Two of his associates — Mithril Capital Management’s Jim O’Neill and Andreessen Horowitz’s Balaji Srinivasan — met with Donald Trump this week to vie for the role of FDA commissioner. Beyond that, Thiel’s big data play Palantir Technologies just entered a profit-sharing partnership with Merck.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!